EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cyteir Therapeutics's enterprise value is $-20.87 Mil.
Cyteir Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-37.72 Mil. Therefore, Cyteir Therapeutics's EV-to-EBITDA for today is 0.55.
The historical rank and industry rank for Cyteir Therapeutics's EV-to-EBITDA or its related term are showing as below:
CYTT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6432.96 Med: 0 Max: 563.76
Current: 0.55
During the past 4 years, the highest EV-to-EBITDA of Cyteir Therapeutics was 563.76. The lowest was -6432.96. And the median was 0.00.
CYTT's EV-to-EBITDA is ranked better than 77.68% of 466
companies
in the Biotechnology industry
Industry Median: 9.35
vs CYTT: 0.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Cyteir Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Cyteir Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cyteir Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Cyteir Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's EV-to-EBITDA falls into.
Cyteir Therapeutics's current Enterprise Value is $-20.87 Mil.
Cyteir Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cyteir Therapeutics's PE Ratio for today is calculated as:
Cyteir Therapeutics's share price for today is $3.01.
Cyteir Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.940.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Cyteir Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your 